Experimental drug shows promise for Hard-to-Treat lymphoma

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients must have histologically or cytologically confirmed relapsed/refractory CD30 low (\<10%) TCL: including peripheral TCL not otherwise specified (PTCL NOS), angioimmunoblastic T cell lymphoma (AITL), hepato-splenic T cell lymphoma (HTCL), adult T cell leukemia/lymphoma (ATLL), enteropathy associated T cell lymphoma (EATL), adult T cell leukemia/lymphoma (ATLL), enteropathy associated T cell lymphoma (EATL), NK T cell lymphoma (NK/TCL) * At least 1 prior chemotherapy regimen * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. ECOG Performance Status (PS) 3 will be permitted if the decreased PS is attributed to the lymphoma * Adequate organ function * Bilirubin ≤1.5X upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3X ULN even in patients with documented hepatic involvement with lymphoma * Serum creatinine clearance ≥30 ml/min * Absolute neutrophil count (ANC) ≥1000/μL (unless documented bone marrow involvement with lymphoma) * Platelet count ≥50,000/μL (unless documented bone marrow involvement with lymphoma) * At least 6 weeks from autologous stem cell transplantation * At least 3 months from allogeneic stem cell transplantation and off immunosuppression and no evidence of graft versus host disease (GVHD) * Previous treatment with brentuximab vedotin will be allowed if it was done 6 months prior to enrollment and patient was not refractory * Measurable disease ≥1.5 cm seen on computed tomography (CT) scan and Fluorodeoxyglucose (FDG) avid disease on positron emission Tomography (PET) scan. Splenomegaly measuring \>12 cm, if attributed to TCL and/or positive bone marrow involvement with lymphoma are also eligible. * Females of childbearing potential must have a negative serum or urine pregnancy test result within 7 days prior to the first dose of study treatment. Women of child-bearing age must agree to use an effective contraception method during the study and for at least 6 months following the last dose of study drug. * Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of study drug. * Subjects must have the ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Anaplastic large cell lymphoma (ALCL) both alk positive and negative * Cutaneous T cell lymphomas except transformed Mycosis fungoides (MF) * Prior treatment with Brentuximab in the last 6 months or previously refractory to Brentuximab Vedotin (BV) or had progressive disease (PD) while on BV * Pregnancy or breast feeding women * Prior malignancy within the past 3 years except non melanoma skin cancer or other localized cancer treated with curative intent * Presence of grade \>2 peripheral neuropathy or patients with the demyelinating form of Charcot-Marie-Tooth syndrome. * Presence of central nervous system (CNS) involvement requiring active treatment * History of progressive multifocal leukoencephalopathy (PML) * Myocardial infarction within the past 6 months * Patients with the following medical conditions that could affect their participation in the study: * any active acute or chronic or uncontrolled infection * liver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitis * a known history of HIV * symptomatic cardiac disease, including congestive heart failure, coronary artery disease, and arrhythmias * Prior hypersensitivity to any component in the ADC formulation * Treatment with chemotherapy or investigational agents within 2 weeks of start of study treatment